
Delta-Fly
4598.TDelta-Fly Pharma, Inc. Price (4598.T)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
7,190,965
(26.9084)%Description
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclin... Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $445-903
- Market Cap 5.75B
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Mr. Kiyoshi Eshima Ph.D.
- IPO Date: October, 12, 2018
- Country: JP
- Currency: JPY
- Headquaters: No Data
- Employees: 13
- Revenue from each product or segment:
Product or Segment | Value: | % - Total | Last 3Y: |
---|

- Revenue by Region
Product or Segment | Value: | % - Total | Last 3Y: |
---|
